ExonHit Issues 8.3M in Bonds for Clinical Development

genomeweb
360dx

ExonHit Issues 8.3M in Bonds for Clinical Development

Feb 02, 2004

NEW YORK, Feb. 2 (GenomeWeb News) - ExonHit Therapeutics has issued €8.3 million ($10.3 million) in convertible bonds to existing shareholders and affiliate companies, the Paris-based company said today.

To read the full story....

...and receive Daily News bulletins.

Already have an account?
Login Now.

Breaking News

Drugs Targeting Lipolysis Could Confer Additional Cardiovascular Benefit, Genetic Analysis Finds
Pregnancy Microbiomes Vary With Time, Body Site, Disease
Quadrant Biosciences Wins $2M NIH Grant for Autism Test
Cepheid Fingerstick HCV Test Receives CE-IVD Clearance
Fleury Group to License IDbyDNA NGS Platform
Long Noncoding RNAs Classified Based on Sequence Motifs

The Scan

NIH's Collins on Harassment

In a statement, National Institutes of Health Director Francis Collins says sexual harassment is "morally indefensible" and "unacceptable."

With Eight Arms and Giant Eyes

Octopuses might owe their intelligence to their liberal alterations to their genes, Cosmos reports.

Missing From Trials

Stat News and ProPublica report that African Americans are underrepresented in cancer clinical trials.

This Week in Cell

In Cell this week: genomic analysis of abdominal aortic aneurysm, effect of probiotics on the microbiome, and more.

Main menu